Business
The Power Play by The Market Herald Releases Interviews With Else Nutrition, Ayurcann Holdings, and Resverlogix
VANCOUVER, BC / ACCESSWIRE / February 22, 2022 / The Power Play by The Market Herald has ann...
About this update from Resverlogix Corp.
[{"type":"text","content":"The Power Play by The Market Herald Releases Interviews With Else Nutrition, Ayurcann Holdings, and ResverlogixVANCOUVER, BC / ACCESSWIRE / February 22, 2022 / The Power Play by The Market Herald has announced the release of new interviews with Else Nutrition, Ayurcann Holdings, and Resverlogix on their latest news.The Power Play by The Market Herald provides investors with a quick snapshot of what they need to know about the company's latest press release through exclusive insights and interviews with company executives.Else Nutrition (TSX:BABY) concludes successful preclinical study of plant-based infant formulaElse Nutrition (BABY) has concluded a preclinical study on its plant-based, soy-free infant formula. This study demonstrates the safety and nutrient bioavailability of the Else infant formula. Hamutal Yitzhak, CEO & Co-Founder of Else Nutrition sat down with Shoran Devi to discuss the news.For the full interview with Hamutal Yitzhak and to learn more about Else Nutrition's news, click here.Ayurcann Holdings (CSE:AYUR) reports record sales and positive operating income in Q2, 2021Ayurcann Holdings Corp. (AYUR) has reported financial and operating results for its second-quarter ending December 31, 2021. Ayurcann reported increased revenues of 106 per cent and increased gross margins of 500 per cent YoY. Igal Sudman, Co-Founder and CEO of Ayurcann sat down with Shoran Devi to discuss the results.For the full interview with Igal Sudman and to learn more about Ayurcann Holdings' results, click here.Resverlogix (TSX:RVX) steps up Phase 2b study for COVID-19 treatmentResverlogix (RVX) has initiated the first Brazilian and a second Canadian site for its Phase 2b clinical trial for COVID-19 treatment. The study aims to evaluate the safety and efficacy of Canadian-developed apabetalone as a potential oral treatment for COVID-19. Donald J. McCaffrey, President & CEO of Resverlogix sat down with Shoran Devi to discuss the study.For the full interview with Donald McCaffrey and to learn more about Resverlogix's study, click here.Interviews for The Power Play by The Market Herald are released daily. To learn more about the companies featured in The Power Play or to explore our other interviews visit The Power Play by The Market Herald.About The Market HeraldThe Market Herald Canada is the leading source of authoritative breaki...